# Aerie Pharmaceuticals (stock symbol: AERI) Logo in transparent PNG format

## Aerie Pharmaceuticals Logo large

### Aerie Pharmaceuticals Logo large Download PNG (20.12 KB)

![Aerie Pharmaceuticals Logo large Download PNG (20.12 KB)](/img/orig/AERI_BIG-049c7b9c.png)

## Aerie Pharmaceuticals Logo icon format

### Aerie Pharmaceuticals Logo icon format Download PNG (14.73 KB)

![Aerie Pharmaceuticals Logo icon format Download PNG (14.73 KB)](/img/orig/AERI-6fa451a7.png)

## About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

1. Website domain: aeriepharma.com
2. Employees: 376
3. Marketcap: $0.75 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
